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Abstract
Objectives. Comorbidities are common in people with axial spondyloarthritis (axSpA). In this systematic review
and meta-analysis, we aimed to: (i) describe the prevalence of commonly reported comorbidities, (ii) compare
comorbidities between axSpA and control populations, and (iii) examine the impact of comorbidity burden on
axSpA outcomes.
Methods. We systematically searched Medline, PubMed, Scopus and Web of Science using a predefined protocol
in accordance with Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines. We
excluded studies of only one comorbid condition or a few closely related diseases within one organ system. Where
possible, meta-analysis was performed using random-effects models.
Results. A total of 40 studies were included for analysis. 36 studies reported prevalence of comorbidities, amount-
ing to a combined sample size of 119 427 patients. The number of comorbidities studied ranged from 3 to 43. The
most prevalent individual comorbidities were hypertension (pooled prevalence 23%), hyperlipidaemia (17%) and
obesity (14%). Eleven studies consistently showed higher prevalence of comorbidities in axSpA than controls, par-
ticularly large differences were seen for depression [pooled odds ratio (OR) 1.80] and heart failure (OR 1.84).
Comorbidities (total number of and individual conditions) were also associated with axSpA disease activity, func-
tional impairment, quality of life, work productivity and mortality.
Conclusions. Comorbidities are common in axSpA, particularly cardiovascular diseases and risk factors. Most
comorbidities were more prevalent in axSpA patients than in control populations. Overall comorbidity burden, and
many individual conditions, were associated with axSpA outcomes including worse disease severity, work product-
ivity and mortality.
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Introduction
Axial spondyloarthritis (axSpA) is a chronic inflammatory
disease predominantly affecting the spine. It can be div-
ided into ‘radiographic’ (ankylosing spondylitis, AS) and
‘non-radiographic’ (nr-axSpA), depending on whether
definitive structural changes are evident on plain
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. Comorbidities are common in axSpA patients, particularly hypertension (prevalence 22%), hyperlipidaemia
(17%) and obesity (14%).
. Comorbidities were more prevalent in axSpA than controls, with 80% higher odds for heart failure and
depression.
. Comorbidities were associated with poorer patient-reported outcomes, work productivity, treatment response
and mortality.
1Musculoskeletal Biology, Institute of Lifecourse and Medical
Sciences, University of Liverpool, 2Department of Academic
Rheumatology, Liverpool University Hospitals and 3School of
Medicine, University of Liverpool, Liverpool, UK
Submitted 12 February 2020; accepted 9 April 2020
Correspondence to: Nicola J. Goodson, Department of Academic












VC The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial




radiographs of sacroiliac joints. Patients with axSpA are
at higher risk of other medical conditions than the gen-
eral population, partly due to shared risk factors, conse-
quences of inflammation or its treatment (e.g. long-term
NSAIDs). The majority of axSpA patients have at least
one comorbid medical condition in addition to any
extra-articular manifestations [1]. The collective ‘burden’
of these comorbidities has been reported to associate
with poorer function, quality of life and work-related out-
comes [2]. They are also important considerations in
routine clinical practice where renal impairment, infec-
tions, cardiovascular and gastrointestinal diseases will
all influence treatment decisions [3]. Some are also key
drivers of mortality [4]. A holistic, patient-centred care
provision model is therefore essential in rheumatology,
yet comorbidity research to inform such practices have
been heterogeneous in design and quality.
The majority of prior research have focused on one or
a few closely related comorbidities in one organ system;
examples include cardiovascular diseases and bone
health. While this approach is valid for assessing the im-
pact of one comorbid disease on axSpA, it does not re-
flect the real-world setting where patients frequently
have multiple inter-related comorbidities. When studies
include several comorbidities, their methods are often
diverse. Some count the number of conditions in varying
lists (often arbitrarily) defined by the researchers, which
may overlook important comorbidities, while others use
indices that are weighted for outcomes unrelated to their
topic of study (e.g. using the Charlson Comorbidity
Index to study functional outcomes).
The aims of this systematic review and meta-analysis
were to: (i) describe the prevalence of commonly
reported comorbidities, (ii) compare the incidence and/
or prevalence of comorbidities between axSpA and con-
trol populations, and (iii) examine the impact of comor-
bidity burden on axSpA outcomes.
Methods
A systematic review was performed in accordance with
the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) guidelines [5]. The proto-
col for this review was pre-registered in advance
(PROSPERO: CRD42019151105). We searched Medline,
PubMed, Scopus and Web of Science for relevant litera-
ture in September 2019, using the following search
term: (ankylosing spondylitis OR axial spondyloarth*)
AND (multimorbid* OR comorbid* OR polymorbid* OR
multi-morbid* OR co-morbid* OR poly-morbid*).
Studies of axSpA (whether defined by classification
criteria or otherwise) were included if they reported the
prevalence or incidence of comorbidities or their impact
on disease outcomes. We also included studies that did
not primarily examine comorbidities but reported their
prevalence in detail. Studies were excluded if they
focused on only one comorbid condition (e.g. stroke
only) or a few closely related diseases in one organ sys-
tem (e.g. cardiovascular diseases only). This is to
distinguish studies of comorbidity from, say, cardiovas-
cular risk. We also excluded studies that used non-
representative sampling (highly selective recruitment or
criteria randomized controlled trials) or had a samples
size of <30 (to avoid unreliable prevalence estimates).
Published conference abstracts were considered, as
some prevalence studies may not be published as full
articles but nevertheless have sufficiently detailed meth-
odology and results. Bibliographies of all eligible studies
were also manually searched to identify additional titles.
Reviews, comments and editorials were excluded.
Two independent reviewers screened titles and
abstracts, assessed full-texts for eligibility and extracted
data from qualifying studies. Any discrepancy at each
stage was resolved through discussion moderated by a
third reviewer. Information from included studies was
extracted into predefined tabulated summaries. We
excluded extra-articular manifestations (EAMs) from our
list of extracted comorbidities, as they share pathogen-
esis with and aid diagnosis of axSpA [6, 7]. Studies
were assessed for risk of bias using adapted versions of
the Newcastle Ottowa Scale (details in supplementary
materials, available at Rheumatology online).
For aims 1 and 2, we performed meta-analyses for
comorbidities reported by at least three studies. Pooled
prevalence estimates were reported as percentages
(95% CI), using random-effects models (DerSimonian-
Laird). Double arcsine transformation was used, as trad-
itional weighting methods are problematic when propor-
tions are close to the bound limits. Heterogeneity of
meta-analysis estimates were presented using the I2
statistic. Funnel plots were used to assess risk of publi-
cation bias. Analyses were performed using MetaXL ver-
sion 5.3 (Sunrise Beach, Australia).
Results
A total of 1522 publications were found from the litera-
ture search. After excluding duplicates, irrelevant and in-
eligible studies, 44 studies remained. Three used data
from the ASAS-COMOSpA study [2, 8, 9], from which the
paper by Nikiphorou et al. was selected because it
restricted to participants fulfilling ASAS criteria. Two used
the OASIS registry [10, 11]; we kept the paper by Stolwijk
et al. as it reported a greater range of comorbidities. The
larger of two studies using United States’ claims data by
Walsh et al. was included [5, 12]. Flowchart of the selec-
tion process is shown in Supplementary Fig. S1, available
at Rheumatology online.
The 40 included studies are summarized in
Supplementary Table S1, available at Rheumatology on-
line. Sample size ranged from 74 to 21 872. A total of 22
studies used European cohorts, seven were from Asia,
six North America, one Argentina, one Australia and four
were multinational. Mean age of study samples ranged
from 29 (China) to 59 (UK). Mean BASDAI ranged from
3.4 (China) to 7.6 (Australian cohort initiating TNFi).
AxSpA was defined using classification criteria in 20
studies (seven using the modified New York criteria
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only, 13 using the ASAS 6mNY criteria), diagnostic
codes in 14, physician diagnosis in three and self-report
in one. The number of comorbidities studied ranged
from three to 43 (excluding EAMs). Most studies used
unvalidated lists, while 13 used a validated index either
directly or indirectly (to inform which comorbidities to in-
clude, e.g. Kang et al. [13]): three used the Charlson
Comorbidity Index (CCI), two the Elixhauser Comorbidity
Index (ECI), three the self-reported comorbidity ques-
tionnaire (SCQ), two the Rheumatic Disease Comorbidity
Index (RDCI), two the multimorbidity index and one the
Functional Comorbidity Index (see reference [14] for
descriptions of each). EAMs were included as comorbid-
ity in a minority (five out of 40 studies), while two con-
sidered valvular heart disease and restrictive lung
disease as EAMs. Two studies also included smoking as
comorbidity. Most studies did not justify their sample
size because they were not dedicated studies of comor-
bidities, thereby losing one score for bias. Taking this
into account, scores were mostly 4–5 out of 6 stars
(Supplementary Table S2 and Fig. S2, available at
Rheumatology online) indicating minimal bias.
Prevalence of comorbidities
A total of 36 studies reported prevalence of individual
comorbidities with a combined sample size of 119 427
patients [1, 2, 5, 11, 13, 15–45]. All studies reported one
or more diseases of the cardiovascular system; 21 stud-
ies included a gastrointestinal or hepatic disorder; 21
included cancers; 18 pulmonary disorders; 16 mental
health disorders (anxiety or depression). The most fre-
quently studied individual comorbidities were hyperten-
sion (33 studies), diabetes (30) and stroke (18); all other
were reported by 16 or fewer studies. Diverticulitis, irrit-
able bowel syndrome, venous thromboembolism and
bronchiectasis are examples of infrequently (reported by
2 studies) included conditions (full list in
Supplementary Table S3, available at Rheumatology
online).
Pooled prevalence estimates of individual comorbid-
ities are summarized in Fig. 1 with further details in
Table 1. The top five most prevalent comorbidities were
hypertension (22.3%), any infection (18.3%), hyperlipid-
aemia (17.1%), obesity (13.5%) and any cardiovascular
disease (CVD, 12.3%). There was significant heterogen-
eity for the majority of meta-analyses. Stratifying by
axSpA definition (i.e. diagnostic code, modified New
York, ASAS6mNY criteria) did not improve heterogen-
eity or give significantly different prevalence estimates
(data not shown). Forrest and funnel plots of the 36
meta-analyses are provided in supplementary materials,
available at Rheumatology online.
Comorbidities in axSpA compared with controls
Eleven studies compared comorbidities between axSpA
and control groups [5, 13, 15–18, 20, 26, 36, 37, 41]. Six
studies selected controls without AS or inflammatory
rheumatic diseases, while five others did not specify or
FIG. 1 Pooled prevalence of individual comorb conditions reported by 3 studies
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selected from the whole population. All studies com-
pared prevalence; nine used pairwise comparisons or
odds ratios (OR) and two used standardized mortality
ratios (SMR). All except one study matched for at least
age and sex. Cardiovascular comorbidities were the
most commonly described. Virtually all individual comor-
bidities were more prevalent in axSpA populations than
matched controls (Supplementary Table S4, available at
Rheumatology online).
For the nine studies reporting OR (or from which OR
would be calculated), comorbidities reported by 3
studies were pooled using meta-analysis (summarized in
Fig. 2 with further details in Table 2). The three most fre-
quently compared comorbidities were hypertension
(axSpA groups had 58% higher odds than controls), dia-
betes (14% higher odds) and ischaemic heart disease
(IHD, 51% higher odds). The largest effect sizes were:
84% higher odds of heart failure in axSpA compared
with controls; and 80% higher odds for depression.
Heterogeneity was high for all meta-analysis estimates.
Forrest and funnel plots for 10 meta-analyses are shown
in supplementary materials, available at Rheumatology
online.
Two studies additionally reported incidence of comor-
bidities after axSpA diagnosis (Table 3). Cook et al.
found higher risk of developing hypertension, myocardial
infarction, stroke, COPD and depression in axSpA
patients compared with controls [18]. When Essers et al.
adjusted for NSAID-use, however, the difference for
myocardial infarction and IHD were no longer signifi-
cantly different between axSpA and controls [20].
Three studies compared comorbidities between male
and females. Bremander et al. showed that the differ-
ence in osteoporosis prevalence between axSpA and
TABLE 1 Meta-analysis estimates for prevalence of individual comorbidities
n Pooled prevalence 95% CI I2, % Range
Any cardiovascular disease 12 12.0 5.8, 19.9 100 2.7, 34.4
Any ischaemic heart disease 15 5.5 3.7, 7.5 99 0.9, 16.2
Angina 6 3.6 1.2, 6.9 96 1.2, 7.0
Myocardial infarction 11 2.2 1.4, 3.1 91 0, 7.2
Heart failure 10 1.8 1.2, 2.4 95 0.5, 5.8
Arrhythmias 7 3.9 1.2, 7.8 98 1.0, 14.0
Stroke 18 1.8 1.3, 2.3 96 0, 5.5
Peripheral vascular disease 9 1.1 0.6, 1.9 97 0.2, 2.8
Hypertension 33 22.8 16.4, 29.8 100 4.5, 73.0
Diabetes mellitus 30 6.0 4.6, 7.5 99 0.3, 18.0
Hyperlipidaemia 11 16.8 10.1, 24.7 100 4.2, 33.1
Hypercholesterolaemia 5 14.6 4.0, 29.6 99 4.3, 27.0
Obesity 7 13.5 2.2, 30.4 100 0.2, 27.3
Any pulmonary disease 8 7.9 2.6, 15.4 99 1.9, 23.4
COPD 8 1.8 0.9, 2.8 94 0.6, 5.0
Asthma 8 4.9 2.9, 7.3 98 0.5, 11.3
Any infection 3 18.2 3.9, 38.4 100 4.6, 32.9
TB 7 1.3 0.5, 2.4 93 0, 3.8
Viral hepatitis 6 3.4 0.9, 7.3 97 0.6, 18.6
HIV 3 0.1 0.04, 0.3 13 0, 0.3
Any GI disease 5 8.4 2.5, 16.9 99 1.0, 31.3
Peptic ulcer 12 6.9 3.3, 11.6 99 1.1, 20.9
Liver disease 9 2.9 0.7, 6.4 99 0, 12.0
Alcohol excess 4 3.2 0.0, 8.3 99 0.3, 9.4
Drug misuse 3 2.7 0.4, 6.6 96 1.1, 4.8
Depression 16 10.9 6.2, 16.7 100 2.0, 31.0
Any cancer 16 3.8 0.7, 9.0 100 0.3, 29.5
Solid cancer 5 3.3 0.3, 8.5 99 0.6, 12.0
Renal disease 15 1.4 1.0, 1.9 93 0.1, 2.7
Anaemia 6 6.0 2.0, 11.7 97 1.0, 14.1
Osteoporosis 12 8.8 5.1, 13.2 99 3.4, 31.0
Fibromyalgia 5 3.6 0.2, 9.7 100 0.4, 13.0
Dementia 4 0.4 0.1, 0.8 74 0, 0.8
Migraine 3 1.9 0.9, 3.3 83 1.3, 3.0
Parkinson’s disease 3 0.3 0.2, 0.4 0 0.1, 0.3
MS 4 0.4 0.3, 0.6 0 0.1, 0.5
Stroke includes cerebrovascular accidents and transient ischaemic attacks.
COPD: chronic obstructive pulmonary disease; GI: gastrointestinal; MS: multiple sclerosis.
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controls were much higher in males than females (SMR
6.98 vs 3.24) but no different for other comorbidities that
they studied [16]. Kang et al. reported significantly
higher odds of migraine (conditional OR 2.3 vs 1.5),
COPD (OR 6.8 vs 2.4) and asthma (OR 1.6 vs 0.8), in fe-
male axSpA vs female controls than the equivalent com-
parison in males [13]. They also found non-significantly
higher odds for IHD (OR 4.5 vs 2.3), alcohol (OR 5.0 vs
1.3) and drug (OR 2.2 vs 1.1) abuse/dependence in
females. Essers et al. reported higher incidence rate
ratios for IHD in females than males (1.72 vs 1.07) [20].
Association between comorbidity burden and
disease outcomes
Seventeen studies reported the association between
comorbidity burden and axSpA outcomes (Table 4). In
the majority of studies, axSpA patients with comorbidity
had higher disease activity and function impairment,
more severe pain and poorer quality of life than those
without. ESR and CRP were generally not significantly
different.
Three studies reported work-related outcomes.
Nikiphorou et al. found that RDCI was associated with
reduced employment, increased time off due to health
reasons (absenteeism) and reduced productivity at work
(presenteeism) [2]. Stolwijk et al. found that the SCQ
score was associated with stopping work due to disabil-
ity, but only in those with BASDAI<4 [11]. Boonen et al.
reported three times higher odds of inability to perform
paid work in AS patients with comorbidities than without
[48].
Two studies examined treatment outcomes. Iannone
et al. reported correlation between a modified version of
RDCI and number of biological drug switches [49]. The
authors also found mRDCI to be a predictor of TNFi dis-
continuation and poor ASDAS remission response.
Lindström et al. found CVD, affective disorders, chronic
lung disease and malignancy to be associated with
increased TNFi discontinuation in unadjusted Cox mod-
els, but not diabetes or chronic kidney disease (CKD)
[28].
Three studies reported mortality outcomes. Lee et al.
studied comorbidity burden using CCI, where each unit
increase was associated with 7% higher odds of all-
cause mortality [50]. Haroon et al. found that dementia
and peripheral vascular disease (PVD) were associated
with increased vascular mortality, but not diabetes,
CKD, IBD or cancer [26]. All comorbidities in the study
by Exarchou et al. were each significant associated with
all-cause mortality; AS patients with chronic pulmonary
disease were at particularly higher risk of death (HR 3.0)
[36].
Discussion
Comorbidities are common and associated with disease
outcomes in axSpA. Meta-analysis pooling results from
FIG. 2 Summary of meta-analysis estimates for odds
ratios comparing comorbidities between axSpA and
control groups
TABLE 2 Meta-analysis estimates for odds ratios (OR) of comorbidities compared between axSpA and control groups
n Pooled OR 95% CI I2, % OR range
Hypertension 9 1.58 1.29, 1.92 98 1.09, 3.01
Any cardiovascular disease 3 1.42 0.999, 2.03 99 1.14, 1.97
Any ischaemic heart disease 7 1.51 1.21, 1.87 87 1.10, 2.74
Heart failure 4 1.84 1.25, 2.73 89 1.42, 2.74
Stroke 6 1.30 1.04, 1.62 81 0.95, 1.80
Peripheral vascular disease 5 1.47 1.10, 1.96 83 1.06, 2.21
Diabetes 8a 1.14 1.001, 1.30 83 0.90, 1.31
Hyperlipidaemia 5 1.18 1.01, 1.39 94 1.02, 1.46
Cancer 5b 1.22 1.01, 1.47 93 0.80, 1.59
Depression 4 1.80 1.45, 2.23 92 1.45, 2.10
aDiabetes without complications selected.
bSolid cancer without metastasis selected.
Stroke: includes cerebrovascular accidents and transient ischaemic attacks.
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>100 000 patients showed the most prevalent individual
comorbidities to be hypertension, hyperlipidaemia and
obesity. There was significant variation in the type and
number of conditions included in each study, which will
impact the precision of estimates. Almost all comorbid-
ities examined were more prevalent in axSpA patients
than age and sex-matched controls, with 80% higher
odds for heart failure and depression. Comorbidities
(total number of and individual conditions) were associ-
ated with patient-reported outcomes, work productivity,
treatment response and mortality.
Despite the high prevalence of many comorbidities,
randomized clinical trials—the gold-standard in
evidence-based medicine—routinely exclude patients
with these conditions. Clinicians should be mindful of
extrapolating results from explanatory trials (i.e. under
ideal conditions), while researchers should invest in
pragmatic trials that measure effectiveness in routine
clinical practice [51]. Comorbidities are essential consid-
erations in the real-world management of axSpA
patients. They influence treatment decisions (e.g. for
NSAIDs and biologics [3]) and preliminary results also
suggest that they impact treatment outcomes [28, 49].
Studies in this review consistently showed higher preva-
lence of comorbidities in axSpA patients than controls.
Yet, in clinical practice, management of comorbidities
for patients with chronic inflammatory rheumatic dis-
eases are often worse than in the general population
[52]. The 2016 EULAR points to consider for comorbid-
ities recommend rheumatology teams to detect and col-
lect information on comorbidities, liaise with appropriate
healthcare providers to treat comorbidities, and repeat
comorbidity reviews [52]. They focused on six conditions
(CVD, malignancies, infections, peptic ulcer, osteopor-
osis and depression) that map almost exactly with high-
prevalence comorbidities in our meta-analysis. It may,
however, be that under-recognised comorbidities have
under-estimated prevalence. Others have suggested
including additional comorbidities [53], but this may be
limited by feasibility in daily practice – the six comorbid-
ities alone require a 93-item reporting form.
Almost all included comorbidities were more prevalent
in axSpA patients than controls. axSpA patients had
markedly higher odds for depression and cardiovascular
diseases than controls. Symptoms of axSpA typically
begin in early adulthood, which is a critical time for
careers, relationships and general social and personal
identity. Disruptive symptoms—sometimes undiagnosed
for many years—may impact life-long mental health tra-
jectory and contribute to depression rates. Unlike RA,
axSpA is not typically associated with high levels of sys-
temic inflammation – a key driver of CVD risk. Higher
CVD prevalence may be related to treatment in addition
to the disease process itself; incidence of myocardial in-
farction and IHD were no different between axSpA and
controls after adjusting for NSAID-use [20]. Heart failure
is downstream of many CVDs; thus, higher odds in
axSpA may reflect the overall burden and severity of
CVDs. It may also be due to more systematic identifica-
tion when considering TNF inhibitors. These results are
consistent with prior studies showing reduced systolic
and diastolic function in axSpA patients compared with
controls [54, 55]. Heart failure can have significant im-
pact on function and quality of life [56], thus optimal
symptom management is important for patients already
burdened by their rheumatic disease.
The presence of comorbidities was consistently asso-
ciated with worse patient-reported axSpA outcomes,
such as the BASDAI and BASFI. Future studies should
complement such analyses by interrogating the
TABLE 3 Studies comparing comorbidity incidence between axSpA patients and controls
Measure of incidence Control group Comorbidity Effect size 95% CI
Cook
2018 [18]
HR (incidence after AS diagno-
sis), adjusted for age and sex
UK biobank participants

























HR (incidence after AS diagno-
sis), adjusted for age, sex,
NSAID use, smoking, BMI and
other medications
CPRD patients without RA,

















COPD: chronic obstructive pulmonary disease; CPRD: Clinical Practice Research Datalink; CVA: cerebrovascular accident;
MI: myocardial infarction.
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TABLE 4 Studies examining the impact of comorbidity on axSpA outcomes
How comorbidity was
examined
Outcome Results (shown as pairwise comparison,






Quality of life (EQ5D) Comorbidity was present in 36%.
AS patients with comorbidity reported lower
QoL than those without (0.36 vs 0.68,
P<0.001) in unadjusted comparison
Salaffi 2009 [47] SCQ BASDAI SCQ was associated with increased BASDAI,






BASFI CCI was not associated with BASFI (ß ¼0.03;







In multivariable linear models, each unit in-
crease in ECI was associated with:
BASDAI (ß¼0.12; 0.07, 0.17),








Comorbidity was present in 51%.
MMI count was associated with:
pain (ß¼0.21; 0.04, 0.38),
ESR (ß¼2.04; 0.65, 3.42),
CRP (ß¼4.93; 2.88, 6.98) in age and sex
adjusted linear models.
Boonen 2001 [48] Presence or absence
(19 comorbidities, not
described)
Work disability (inability to
perform paid work)
Comorbidity was present in 41%.
Odds of work disability higher in AS patients
with comorbidities (OR 3.15; 1.96, 5.09)





Quality of life (SF36)
Work disability (stopped
due to disability)
SCQ and mSCQ were associated with BASFI,
but CCI and RDCI were not.
SCQ and mSCQ were associated with SF36,
but CCI and RDCI were not.
SCQ and mSCQ were associated with work
disability in BASDAI<4 (but not 4); CCI and
RDCI were not.
Garip 2016 [23] Presence or absence (9
comorbidities)
Multiple outcomes Comorbidity was present in 28%.
In unadjusted comparisons, patients with
comorbidities reported higher BASDAI (5.1 vs
3.7), BASMI (4.3 vs 3.2), BASFI (5.8 vs 2.4)
and energy (52 vs 30), all P<0.05.
Differences were not significant for sleep (41 vs
33), social isolation (38 vs 29) or emotional
reactions (41 vs 35).
Ljung 2018 [29] Each of 4 comorbidity
categories
Multiple outcomes In multivariable logistic regression: arrhythmia/
valvular disease, atherosclerosis, fractures
and obstructive sleep apnoea were not asso-
ciated with peripheral or extra-articular mani-
festations, BASMI or CRP.
Nikiphorou 2018
[2]
RDCI Multiple outcomes In multilevel multivariable linear or logistic mod-
els, RDCI was associated with:
BASFI (ß¼0.37; 0.30 to 0.43),
EQ5D (ß¼0.03; 0.04 to 0.02),
Work status (OR 0.83; 0.76 to 0.91),
Absenteeism (OR 1.18; 1.04 to 1.34),





Multiple outcomes Comorbidity was present in 55%.
In unadjusted comparisons: axSpA with vs
without comorbidity had similar ESR (median
11 vs 10, P¼0.09) and CRP (3 vs 2.5,
P¼0.18); similar peripheral and extra-articular
features, except psoriasis (21 vs 15%,
P¼0.02) and peripheral arthritis (38 vs 27%,
P<0.01),
Presence of comorbidity associated with
higher:
BASDAI (ß¼0.70; 0.34, 1.05),
BASMI (ß¼0.45; 0.09, 0.80),
BASFI (ß¼0.50; 0.23, 0.78),
HAQ (ß¼0.07; 0.00, 0.13),
ASQoL (ß¼0.87; 0.28, 1.46).
(continued)
Prevalence and impact of comorbidities in axial spondyloarthritis
https://academic.oup.com/rheumatology iv53
contribution of individual comorbidities, comorbidity
clusters [1], as well as their combined impact. There is
also a need to examine how robust various outcomes
(e.g. BASDAI vs ASDAS) are to comorbidities such as
depression, as they may influence assessment of treat-
ment response. Whether outcomes such as treatment
response and work productivity can be improved by
optimizing management of certain comorbidities is an
important unanswered question.
Methodological approach for comorbidity research
could benefit from similar standardization as suggested




Outcome Results (shown as pairwise comparison,
or ‘effect size; 95% confidence interval’)
Number of
comorbidities
The number of comorbidities was also signifi-
cantly associated with:
BASDAI (ß¼0.23; 0.09, 0.37),
BASMI (ß¼0.20; 0.05, 0.34),
BASFI (ß¼0.21; 0.10, 0.32),
HAQ (ß¼0.03; 0.01, 0.06),
ASQoL (ß¼0.25; 0.02, 0.49).
Zhao 2019 (UK) [1] Presence or absence
(38 comorbidities
based on MMI)
Multiple outcomes Comorbidity was present in 61%.
In unadjusted comparisons, presence of
comorbidity not associated with peripheral or
EAM. Patients with comorbidity had worse:
EQ5D (0.5 vs 0.6),
global health (5.2 vs 4.8),
fatigue (6.3 vs 5.1),
BASDAI (6.4 vs 5.6),
spinal pain (7.0 vs 6.0),
BASFI (6.8 vs 4.5), all P<0.05; but not ESR
(13 vs 10mm/h) or CRP (5 vs 4mg/l).
In multivariable linear models, anxiety/depres-
sion and fibromyalgia/IBS clusters were asso-




Each of 6 comorbidities TNFi discontinuation CVD (HR 1.24; 1.08, 1.43),
Affective disorder (HR 1.81; 1.54, 2.13),
Chronic lung disease (HR 1.49; 1.22, 1.82),
Malignancy (HR 1.36; 1.06, 1.74), were associ-
ated with TNFi discontinuation in unadjusted
Cox models, but not Diabetes (HR 1.36; 0.99,
1.87) or CKD (HR 0.79; 0.41, 1.52).
Iannone 2018 [49] modified RCDI (adding
obesity and renal
disease)
Biologic drug use In SpA patients, mRDCI correlated significantly
with the number of biological drug switches
(Spearman’s rank coefficient 0.26, P-value
unreported) mRCDI was a significant inde-
pendent predictor of drug discontinuation
(HR 1.53; 1.02, 2.29) and ASDAS remission
(HR 0.43; 0.20, 0.92) in multi-adjusted Cox
models.





Dementia (HR, 2.62; 1.32, 5.23) and PVD (HR,
6.79; 2.45, 18.84) were significantly associ-
ated with vascular mortality, but not diabetes,
CKD, IBD or cancer.
Exarchou 2016
[36]
Each of 5 ‘general’
comorbidities
Mortality CVD (HR 1.99; 1.58, 2.49),
DM (HR 1.92; 1.51, 2.45),
Chronic pulmonary disease (HR 3.03; 2.27,
4.05),
Malignancy (HR 1.67; 1.32, 2.12),
Infections (HR 2.01; 1.68, 2.34) were each inde-
pendent predictors of mortality in separate
multi-adjusted Cox models.
Lee 2018 [50] CCI Mortality
Disability (based on spine
mobility and radiographic
changes)
In multivariable logistic models, CCI was asso-
ciated with increased all-cause mortality (OR
1.07; 1.01, 1.13), but not physical disability
(OR 1.01; 0.95, 1.08).
aUnpublished data. Absenteeism: time off due to health reasons; CCI: Charlson Comorbidity Index; ECI: Elixhauser
Comorbidity Index; MMI: multimorbidity index; Presenteeism: reduced productivity at work; RDCI: Rheumatic Disease
Comorbidity Index; SCQ: self-reported comorbidity questionnaire; Work status: working or not.
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comorbidities in this review ranged from 3 to 43. Most
studies used author-defined lists that were not validated
and selection of diseases was seldom justified. While all
studies consistently included CVDs, some important
conditions were underrepresented, such as fibromyalgia,
alcohol or drug abuse [58] and neurological disorders.
Validated comorbidity indices can include rare comor-
bidities in axSpA (e.g. AIDS and dementia) but not com-
mon and important conditions (e.g. depression [59]).
None have been validated for use in axSpA patients ex-
cept the modified SCQ. Stolwijk et al. showed that CCI
poorly correlated with most axSpA outcomes (e.g.
Spearman’s rho¼0.01 for BASDAI) while both CCI and
RDCI were poorly associated with BASFI and quality of
life (Short Form 36) in multivariable analyses [11].
Validation studies in axSpA are needed for other indices
and comorbidity collection based on the ‘EULAR 6’.
Studies should avoid using weighted indices that have
not been validated for their main outcome of interest
(e.g. CCI or ECI for functional impairment [21, 44]).
Meta-analysis results should be interpreted with limi-
tations in mind. There was significant heterogeneity in
the measurement of comorbidities and relative lack of
data on severity. Study samples also differed in age,
disease severity and other characteristics. The duration
of study in which comorbid diseases were assessed
was also variable. These factors will impact pooled
prevalence estimates but also highlights the need for
greater standardization for future research. Some case-
control studies did not explicitly exclude patients with
AS or other chronic inflammatory rheumatic diseases
from their control population. Comorbidity prevalence in
these control populations may therefore be inflated. This
is unlikely to meaningfully change the overall result, as
inflammatory rheumatic diseases will be uncommon
among controls. Once patients develop symptoms of or
are diagnosed with axSpA, it is likely that increased
healthcare interaction will result in improved identifica-
tion of comorbidities; therefore, prevalence may be
higher than controls by this explanation alone. Well-
established comorbidities such as hypertension may
undergo more systematic screening and diagnosis than
others (e.g. fibromyalgia or depression); results from
cases-control comparisons will be inflated for the for-
mer group of comorbidities. We were unable to com-
pare comorbidity burden between radiographic and
non-radiographic axSpA. Stratified meta-analyses (by
classification criteria) did not reveal statistically signifi-
cant differences in prevalence estimates, which is con-
sistent with the findings of one prior study [33].
In summary, comorbidities are common in axSpA,
particularly cardiovascular diseases and risk factors.
These items were consistently included in assessments
of comorbidities, but diseases belonging to pulmonary,
mental health and neurological systems were less fre-
quently included. The vast majority of comorbidities
assessed were more prevalent in axSpA patients than in
control populations. Overall comorbidity burden, and
many individual conditions, were associated with axSpA
outcomes including disease severity, work productivity
and mortality. Systematic and repeated assessments
should therefore be integrated into routine clinical prac-
tice to ensure holistic patient-centred management.
Additional studies are needed to validate comorbidities
indices for axSpA research.
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proposals to reduce comorbidity in patients with chronic
inflammatory rheumatic diseases: comment on ‘Points to
consider for reporting, screening for and preventing
selected comorbidities in chronic inflammatory rheumatic
diseases in daily practice: a EULAR initiative’ by Baillet
et al. Ann Rheum Dis 2016;75:e55.
54 Midtbø H, Semb AG, Matre K et al. Left ventricular
systolic myocardial function in ankylosing spondylitis.
Arthritis Care Res 2019;71:1276–83.
55 Chen Y, Chung H-Y, Zhao C-T et al. Left ventricular
myocardial dysfunction and premature atherosclerosis in
patients with axial spondyloarthritis. Rheumatology 2015;
54:292–301.
56 Juenger J. Health related quality of life in patients with
congestive heart failure: comparison with other chronic
diseases and relation to functional variables. Heart 2002;
87:235–41.
57 Radner H, Chatzidionysiou K, Nikiphorou E et al. 2017
EULAR recommendations for a core data set to support
observational research and clinical care in rheumatoid
arthritis. Ann Rheum Dis 2018;77:476–9.
58 Zhao SS, Solomon DH, Goodson NJ. Comment on:
comorbidity burden in axial spondyloarthritis: a cluster
analysis: reply. Rheumatology 2020;59:692–3.
59 Zhao S, Thong D, Miller N et al. The prevalence of
depression in axial spondyloarthritis and its association
with disease activity: a systematic review and meta-
analysis. Arthritis Res Ther 2018;20:140.
Prevalence and impact of comorbidities in axial spondyloarthritis
https://academic.oup.com/rheumatology iv57
